Cargando…

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer

BACKGROUND: Fluoropyrimidine plus platinum chemotherapy remains the standard first line treatment for gastric cancer (GC). Guidelines exist for the clinical interpretation of four DPYD genotypes related to severe fluoropyrimidine toxicity within European populations. However, the frequency of these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cordova-Delgado, Miguel, Bravo, María Loreto, Cumsille, Elisa, Hill, Charlotte N., Muñoz-Medel, Matías, Pinto, Mauricio P., Retamal, Ignacio N., Lavanderos, María A., Miquel, Juan Francisco, Rodriguez-Fernandez, Maria, Liao, Yuwei, Li, Zhiguang, Corvalán, Alejandro H., Armisén, Ricardo, Garrido, Marcelo, Quiñones, Luis A., Owen, Gareth I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444616/ https://www.ncbi.nlm.nih.gov/pubmed/34525956 http://dx.doi.org/10.1186/s12885-021-08745-0

Ejemplares similares

A Molecular Stratification of Chilean Gastric Cancer Patients with Potential Clinical Applicability
por: Pinto, Mauricio P., et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
por: Cordova-Delgado, Miguel, et al.
Publicado: (2019)

Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis
por: Wu, Lili, et al.
Publicado: (2021)

Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
por: Owen, Gareth I., et al.
Publicado: (2018)

Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients
por: Pinto, Mauricio P., et al.
Publicado: (2022)

The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies
por: Wang, Tao, et al.
Publicado: (2019)

Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy
por: Seo, Seyoung, et al.
Publicado: (2019)

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
por: Jung, Hyun Ae, et al.
Publicado: (2013)

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy
por: Koo, Dong-Hoe, et al.
Publicado: (2021)

The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer
por: Fouad, Mariam Ahmed, et al.
Publicado: (2021)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer
por: Kim, Ryul, et al.
Publicado: (2022)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
por: Iachetta, Francesco, et al.
Publicado: (2019)

The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer
por: Alarcón, María Alejandra, et al.
Publicado: (2020)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
por: Nakano, Shintaro, et al.
Publicado: (2020)

The Role of Vasospasm and Microcirculatory Dysfunction in Fluoropyrimidine-Induced Ischemic Heart Disease
por: Fabin, Natalia, et al.
Publicado: (2022)

Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective
por: Pinto, Mauricio P., et al.
Publicado: (2018)

Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
por: Del Re, Marzia, et al.
Publicado: (2010)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management
por: Jurczyk, Michał, et al.
Publicado: (2021)

A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology
por: Lee, In-Seob, et al.
Publicado: (2022)

A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy
por: Del Re, Marzia, et al.
Publicado: (2014)

A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs
por: Sun, Xiaomeng, et al.
Publicado: (2022)

A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature
por: Conti, Valeria, et al.
Publicado: (2020)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment
por: Deac, Andrada-Larisa, et al.
Publicado: (2020)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
por: Seo, Seyoung, et al.
Publicado: (2016)

Recurrent cardiotoxicity in a fluoropyrimidine treated cancer patient – case report and practical recommendations
por: Deac, Andrada Larisa, et al.
Publicado: (2023)

Parental and individual predictors of trajectories of depressive symptoms in Chilean adolescents
por: Cumsille, Patricio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qk3aufc014h4745463vneoen0a